Overview

Eligibility

Design Details

Arms & Interventions

Outcome Measures

Trial Sites

Source: NCT03577028

Terminated

Study of HPN424 in Patients With Advanced Prostate Cancer

Interventional

Phase 1/2

University of Colorado Hospital

Sponsor: Harpoon Therapeutics

Last Updated: January 25, 2023
Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.

An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy

Treatment Category

Other Drugs

Required Mutations

None

Trial Started

July 24, 2018

Last Updated by Sponsor

January 25, 2023

Estimated Completion

March 1, 2023

Contact Study

Name:N/A

Email:N/A

Phone:N/A

Eligibility

Inclusion Criteria

1. Male patients ≥18 years of age at the time of signing informed consent

2. Histologically or cytologically confirmed adenocarcinoma of the prostate

3. Progressive metastatic castrate-resistant prostate cancer (mCRPC):

1. Serum testosterone levels less than 50 ng/dL (or ≤0.50 ng/mL or 1.73 nmol/L) within 28 days prior to start of study drug

2. Radiographic evidence of metastatic disease

3. Disease progression on the prior systemic regimen, per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria

i. A sequence of at least 2 rising PSA values measured at a minimum of 1 week apart with a 2 ng/mL minimum starting value, or

ii. Appearance of two or more new lesions on bone scans, or iii. Progressive visceral disease, or

iv. Progressive nodal disease; previously normal (<1.0 cm) lymph nodes must have grown by ≥5 mm in the short axis from baseline or nadir and be ≥1.0 cm in the short axis to be considered to have progressed

4. Must have received at least 2 prior systemic therapies approved for mCRPC

5. Ongoing androgen depletion therapy with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration)

6. For patients previously treated with first generation anti-androgens, discontinuation must have occurred ≥4 weeks (for flutamide or nilutamide) or ≥6 weeks (for bicalutamide) prior to start of study drug, with no evidence of an anti-androgen withdrawal response (i.e., no decline in serum PSA)

7. For patients previously treated with a second-generation anti-androgen (e.g., enzalutamide or equivalent) or with abiraterone acetate, discontinuation must have occurred 2 weeks or 5 half-lives prior to start of study drug

8. For patients previously treated with systemic chemotherapy, targeted therapy, immunotherapy, or treatment with an investigational anticancer agent, discontinuation must have occurred ≥2 weeks, or at least 4 half-lives (up to 4 weeks), whichever is longer, prior to start of study drug.

9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

10. Adequate bone marrow function, including:

1. Absolute neutrophil count (ANC) ≥1500/mm3 or ≥1.5 x 109/L

2. Platelets ≥100,000/mm3 or ≥100 x 109/L

3. Hemoglobin ≥9 g/dL (no transfusions allowed within 1 week prior to screening)

11. Adequate renal function, including:

a. Estimated creatinine clearance ≥50 mL/min as calculated using the method standard for the institution

12. Adequate liver function, including:

1. Total serum bilirubin ≤1.5 x upper limit of normal (ULN) unless the patient has documented Gilbert syndrome in which case the maximum total serum bilirubin should be 5 mg/dL

2. Aspartate and Alanine transaminase (AST and ALT) ≤2.5 x ULN

13. Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1 except for adverse events (AEs) not constituting a safety risk per the Investigator

14. If of reproductive potential, willing to use 1 effective method of contraception (as defined in this protocol) during the treatment period, if partner is a female of childbearing potential.

15. Willing to complete all scheduled visits and assessments at the institution administering therapy

16. Able to read, understand and provide written informed consent

Exclusion Criteria

1. Previously treated or current brain metastases

2. Untreated spinal cord compression. Participants must be neurologically stable off steroids for at least 4 weeks prior to first dose of study drug

3. Ongoing treatment with anti-tumor necrosis factor (TNF) alpha therapies, systemic corticosteroids (prednisone dose >10 mg per day or equivalent), or other immune suppressive drugs

4. History of or known or suspected autoimmune disease (exception(s): patients with vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at Screening are allowed)

5. History of clinically significant cardiovascular disease such as symptomatic congestive heart failure (CHF), uncontrolled hypertension defined as sustained BP >150 mmHg systolic, or >100 mmHg diastolic despite optimal antihypertensive treatment (BP must be controlled at screening), unstable angina pectoris, clinically significant cardiac arrhythmias, history of stroke (including TIA, or other ischemic event) within 6 months before first dose of study drug, myocardial infarction within 6 months before first dose of study drug, history of thromboembolic event within 3 months before first dose of study drug

6. Known active or chronic hepatitis B or hepatitis C as demonstrated by hepatitis B surface antigen (HBsAg) positivity and/or anti-hepatitis C virus (HCV) positivity, respectively, or known history of human immunodeficiency virus (HIV) seropositive status

7. Clinically active liver disease, including liver cirrhosis of Child-Pugh class B or C

8. Second primary malignancy that has not been in remission for greater than 3 years. Exceptions that do not require a 3-year remission: non-melanoma skin cancer, resected melanoma in situ, or non-muscle invasive urothelial carcinoma

9. In the judgment of the Investigator, patient has a clinically significant concurrent illness or psychological, familial, sociological, geographical, or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol

10. Any serious underlying medical or psychiatric condition (e.g., alcohol or drug abuse), dementia or altered mental status or any issue that would impair the ability of the patient to understand informed consent or that in the opinion of the Investigator would contraindicate the patient's participation in the study or confound the results of the study

11. Known hypersensitivity, allergies, or intolerance to immunoglobulins, or to any excipient contained in HPN424 (see Investigator's Brochure)

12. Is a participant or plans to participate in another interventional clinical study, while taking part in this protocol. Participation in an observational study is acceptable

Do you think this trial is incorrectly appearing?

Design Details

AllocationNon-Randomized

Intervention ModelSequential Assignment

MaskingNone (Open Label)

Number to Enroll110

Arms & Interventions

Arms

Interventions

Type: Experimental

Description: HPN424 will be administered once weekly via IV infusion or subcutaneously with dose escalation until an estimated therapeutic dose level has been reached.

Interventions:

HPN424 In Part 1 (Dose Escalation)
HPN424 In Part 2 (Dose Expansion)

Outcome Measures

Primary Outcome Measures

Part 1: Number and severity of dose limiting toxicities (DLTs) of HPN424Baseline through end of Cycle 2 (each cycle is 21 days)

Assess safety and tolerability at increasing dose levels of HPN424 in successive cohorts of patients with metastatic castrate resistant prostate cancer (mCRPC) to select the recommended Phase 2 dose(s) (RP2D), and dosing regimen for further investigation by measuring incidence of DLTs.

Part 2: Overall response rate (ORR) as assessed by PCWG3 criteria for responseup to 4 years

Evaluate preliminary clinical efficacy of HPN424 at recommended phase 2 dose (RP2D) by determining ORR as measured by bone scans, CT/MRI and prostate specific antigen (PSA) levels.

Secondary Outcome Measures

Part 1 and 2: Adverse events (NCI CTCAE version 5.0)up to 4 years

Evaluate the overall safety profile of HPN424 administered by IV infusion or SC injection, as measured by adverse events.

Part 1: Progression-free survival (PFS) using PCWG3 criteriaup to 4 years

Evaluate preliminary clinical anti-tumor activity by measuring PFS.

Part 1: Duration of response (DOR) using PCWG3 criteriaup to 4 years

Evaluate preliminary clinical anti-tumor activity by measuring DOR.

Part 1: Overall survival (OS)up to 4 years

Evaluate preliminary clinical anti-tumor activity by measuring OS.

Part 1: Prostate Specific Antigen (PSA) levelsup to 4 years

Evaluate preliminary clinical anti-tumor activity by measuring PSA levels in blood.

Part 1 and 2: Pharmacokinetics of HPN424up to 4 years

Characterize single dose and multiple dose PK of HPN424 following IV administration by measuring levels of HPN424 in blood serum.

Part 1 and 2: Incidence of anti-drug antibodies (ADA) against HPN424up to 4 years

Evaluate the immunogenicity of HPN424 by assessing anti-drug antibodies in blood serum.

Part 1 and 2: Effects of HPN424 on circulating lymphocytes and systemic soluble immune factorsup to 4 years

Characterize the impact of HPN424 on activation of circulating lymphocytes and on systemic soluble immune factors by immunophenotyping of lymphocytes in whole blood and measuring cytokines in serum.